Ascentage
@ascentagepharma.com
Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Our expertise is in designing inhibitors of protein-protein interactions (PPIs) to restore apoptosis, or programmed cell death.
Ascentage's Company Logos
Ascentage's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#006CB8
Science Blue
0, 108, 184
205, 100, 36
100, 41, 0, 28
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About Ascentage
Ascentage Pharma is a leading biopharmaceutical company based in China with a global focus. It is one of the earliest Chinese companies dedicated to the development of innovative drugs. The company specializes in the development of novel drugs for the treatment of cancer, hepatitis B, and age-related diseases.
In October 2019, Ascentage Pharma went public on the Main Board of the Hong Kong Stock Exchange with the stock code 6855. HK. Ascentage Pharma has developed its proprietary protein-protein interaction targeted drug design platform, which is at the forefront of research in the field of apoptosis pathway drugs.
The company has a pipeline of nine small molecule drugs that have entered clinical development, including inhibitors of key proteins in the apoptosis pathway such as Bcl-2, IAP, and MDM2-p53, as well as inhibitors targeting kinase mutations in cancer therapy. Currently, Ascentage Pharma is conducting more than 40 Phase I/II clinical trials in China, the United States, Australia, and Europe. Their flagship product, Orelabrutinib (trade name: Nalikens), which is used to treat resistant chronic myeloid leukemia, has been granted priority review and breakthrough therapy designation by the China National Medical Products Administration (NMPA).
It has also received fast-track designation from the US FDA and orphan drug designation from both the US FDA and the European Medicines Agency (EMA). With a strong research and development capability, Ascentage Pharma has established a global intellectual property layout and collaboration with leading biotechnology and pharmaceutical companies such as UNITY, MD Anderson, Mayo Clinic, Dana-Farber Cancer Institute, Merck, AstraZeneca, and Pfizer. The company has assembled an international team of experts with extensive experience in innovative drug research and clinical development, and is actively building a high-standard commercial production and marketing team.
Ascentage Pharma is committed to accelerating the clinical development progress of its pipeline and fulfilling its mission of addressing unmet clinical needs of patients in China and around the world. Their culture is guided by a mission to solve clinical needs, a vision to become a leading Chinese and world-class innovative drug company, and values that prioritize patients, innovation, and scientific support
